Pfizer Launches Analytics Gateway In India

Pfizer Inc. has launched its first-ever dedicated commercial analytics centre in India, named the ‘Analytics Gateway’. 

In a press statement on Thursday, the company informed that this new capability centre, based in Mumbai, marks a significant milestone in Pfizer’s global commercial strategy and will support its operations in over 140 countries outside the United States. The Analytics Gateway aims to revolutionise the company's approach to marketing and sales by leveraging cutting-edge data analytics, artificial intelligence (AI), and insights.

The centre brings together a highly skilled team of data science and analytics experts, who will accelerate Pfizer's efforts to modernise its marketing strategies and create a more agile sales force. By utilising AI-driven solutions, the Analytics Gateway will contribute to enhancing commercial effectiveness, allowing Pfizer to expand its reach and bring more medicines to patients across India and around the world.

Xingchu Liu, Chief Commercial Analytics & AI Officer at Pfizer, highlighted the centre's potential: “The Analytics Gateway is an important catalyst to reshape healthcare, transforming how we deliver breakthroughs at lightspeed, enabling us to deliver life-changing therapies to patients. We are confident that the setup of this capability centre in India will have a positive impact on Pfizer’s ability to make informed, data-driven decisions that will prove valuable to patients and customers around the world.”

Meenakshi Nevatia, Country President of Pfizer India, expressed her excitement about the launch stating,  “I am excited about the launch of the Pfizer Analytics Gateway in India. It is an important recognition of the skilled talent in data science and analytics that India can offer to the globe, and strengthens Pfizer’s presence in our country. The actionable insights generated by the Analytics Gateway will power up our global commercial engine as we modernise healthcare to meet the evolving needs of patients in India and worldwide and deliver strong patient outcomes.”